Sparlon User Fee Date Extended To August
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has extended the user fee date for Cephalon's attention deficit/hyperactivity disorder treatment Sparlon (modafinil) to Aug. 22, the company said April 24
You may also be interested in...
September Launch Eyed For Cephalon/J&J’s Sparlon
Cephalon plans to launch the attention deficit/hyperactivity disorder treatment Sparlon (modafinil) with partner Johnson & Johnson in September to take advantage of students returning to school, provided FDA approves the product by its Aug. 22 user fee date, Cephalon said
September Launch Eyed For Cephalon/J&J’s Sparlon
Cephalon plans to launch the attention deficit/hyperactivity disorder treatment Sparlon (modafinil) with partner Johnson & Johnson in September to take advantage of students returning to school, provided FDA approves the product by its Aug. 22 user fee date, Cephalon said
Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials
Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.